Omeros (OMER) said Thursday that its pivotal trial of narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy met its primary endpoint in overall survival.
The company said an independent analysis compared overall survival of the trial's 28 patients with
over 100 similarly high-risk patients who did not receive narsoplimab treatment, and results showed "statistically significant superiority" of overall survival data from the trial's patients.
Omeros said it plans to resubmit the biologics license application for narsoplimab to the US Food and Drug Administration as soon as possible.
Shares of Omeros were up over 48% in early trading.
Price: 11.08, Change: +3.62, Percent Change: +48.53
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。